Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Axe Cap view

Royalty Pharma’s Blockbuster Bet: Worth the Risk?

Royalty Pharma offers diversified drug royalties but has limited local relevance for JSE investors.

Royalty Pharma’s model is intriguing—owning royalties on 16 blockbuster drugs spreads risk and smooths income. Its strong returns on capital and potential for multiple expansion underpin a compelling story in the US biotech space. But South African investors should note that RPRX is not listed on the JSE, meaning any direct exposure requires navigating USD/ZAR currency risk and trading on foreign exchanges. The rand’s recent volatility could amplify gains or losses here. While diversified royalties sound safer than backing a single pharma stock, risks remain: share dilution from issuing new shares and stiffening global pharma competition might erode future returns. For local banks or retailers, this complexity and currency exposure make Royalty Pharma less appealing. Keep an eye on USD/ZAR if you’re tempted—for now, this is not a sector or stock that maps neatly to South Africa’s market. this is just our opinion and not financial advice